Genmab’s CEO Jan van de Winkel has said he would consider spinning out a smaller autoimmune diseases biotech, while ruling out any interest in a merger with big pharma.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,